Competition Act claim alleges that Canadians are being overcharged for prescription drugs

Morganti Legal and McKenzie Lake Lawyers LLP, are representing Canadian pharmacies and consumers that allege that Pfizer Canada Inc abused the Canadian patent system in order to obtain exclusive rights in Canada to sell the pharmaceutical drug pregabalin sold under the trade name Lyrica. Pfizer’s activities resulted in it enjoying 100% of the Canadian market for pregabalin, e.g., without competition from lower priced generics.

Lyrica is indicated for use in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and the pain associated with fibromyalgia.

The claims asserted against Pfizer Canada include interference with economic interest and unjust enrichment seeking the return of the overcharges plus interest. If you purchased Lyrica between April 1, 2011 and February 4, 2013, please contact us for further information at info@morgantilegal.com or toll-free at (888) 226-0845.

Morganti Legal is a law firm that investigates, litigates, and resolves economic and financial disputes in Canada and the United States. Andrew Morganti has successfully represented consumers seeking the return of overcharges involving Synthroid (MDL No. 1182), Lorazepam and Clorazepate (MDL No. 1290), Cardizem CD (MDL No. 1278), Coumadin (MDL No. 1232), and Relafen (01-cv-1222).

Read More